(Q40976212)

25 September 2017

1 reference

title

An international perspective on anticholinergic therapy (English)

1 reference

25 September 2017

K R Chapman

1

1 reference

25 September 2017

language of work or name

English

0 references

publication date

1 January 1996

1 reference

American Journal of Medicine

25 September 2017

published in

1 reference

25 September 2017

volume

100

1 reference

25 September 2017

issue

1A

1 reference

25 September 2017

page(s)

2S-4S

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980013-1

25 September 2017

1 reference

Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980013-1

Management of chronic obstructive pulmonary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980013-1

The role of anticholinergic bronchodilators in adult asthma and chronic obstructive pulmonary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980013-1

A comparison of the bronchodilator activity of Sch 1000 and salbutamol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980013-1

Ipratropium bromide, salbutamol and prednisolone in bronchial asthma and chronic bronchitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980013-1

Synergism between ipratropium and theophylline in asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980013-1

The addition of an aerosol anticholinergic to an oral beta agonist plus theophylline in asthma and bronchitis. A double-blind single dose study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980013-1

Anticholinergic and sympathomimetic combination therapy of asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980013-1

A place for ipratropium bromide in the treatment of severe acute asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980013-1

Ipratropium bromide in acute asthma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980013-1

Comparison of nebulized salbutamol with nebulized ipratropium bromide in acute asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980013-1

Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980013-1

Nebulized ipratropium bromide in the treatment of acute asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980013-1

Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980013-1

Frequent administration by inhalation of salbutamol and ipratropium bromide in the initial management of severe acute asthma in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980013-1

Should ipratropium bromide be added to beta-agonists in treatment of acute severe asthma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980013-1

Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbations with the addition of ipratropium bromide to β-agonist therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980013-1

10.1016/S0002-9343(96)80013-1

7 January 2021

Identifiers

DOI

1 reference

25 September 2017

1 reference